Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy. An evidence‐based rationale was used to develop individualized mavacamten dosing, guide...

Descripción completa

Detalles Bibliográficos

Autores principales:	Anjali T. Owens, Milind Desai, Matthew T. Wheeler, Anna Rodonski, Samira Merali, Amy J. Sehnert, Sara Saberi
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2024-09-01
Colección:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Materias:	echocardiogram individualized dosing left ventricular ejection fraction left ventricular outflow tract gradient mavacamten obstructive hypertrophic cardiomyopathy
Acceso en línea:	https://www.ahajournals.org/doi/10.1161/JAHA.124.033767
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!